Beta

Apollomics, inc.APLM.US Overview

US StockHealthcare
(No presentation for APLM)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

APLM AI Insights

APLM Overall Performance

APLM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

APLM Recent Performance

-2.58%

Apollomics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

APLM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check APLM's Trend

APLM Key Information

APLM Valuation Metrics

APLM Profile

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Price of APLM

APLM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

APLM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-50.98
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.12
PB Ratio
8.15
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-6.56%
Net Margin
-235.10%
Revenue Growth (YoY)
7957.24%
Profit Growth (YoY)
-628.62%
3-Year Revenue Growth
409.39%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-50.98
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.12
PB Ratio
8.15
Price-to-FCF
-
Gross Margin
-6.56%
Net Margin
-235.10%
Revenue Growth (YoY)
7957.24%
Profit Growth (YoY)
-628.62%
3-Year Revenue Growth
409.39%
3-Year Profit Growth
-100.00%

  • When is APLM's latest earnings report released?

    The most recent financial report for Apollomics, inc. (APLM) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APLM's short-term business performance and financial health. For the latest updates on APLM's earnings releases, visit this page regularly.

  • How much debt does APLM have?

    As of the end of the reporting period, Apollomics, inc. (APLM) had total debt of 643K, with a debt ratio of 0.1. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does APLM have?

    At the end of the period, Apollomics, inc. (APLM) held Total Cash and Cash Equivalents of 3.28M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.